Canaccord raised the firm’s price target on TransMedics to $102 from $96 and keeps a Buy rating on the shares. The firm continues to believe US Heart needs to gain more traction for the company to be successful longer-term and caution investors on expectations regarding quarterly revenue outperformance given NOP penetration near 100% and expectations for aviation to reach 75% of NOP case revenue in Q4/24.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TMDX:
